Sanofi's Dupixent rolls on, but US flu shots took backseat to COVID-19 boosters in the fourth quarter

Sanofi’s influenza business did gangbusters in Europe for the last three months of the year. Across the pond in the U.S., however, the shifting COVID-19 vaccination landscape fueled a meaty sales decline, the company said on a call with investors Friday.